Featured
| Dec 23 | GEMMABio Pioneers Affordable Gene Therapies with $34M Seed Funding read more » |
| Dec 19 | A Phase 3 Ready DMD Gene Therapy, a Clinical Trial to Offset AAV Neutralizing Antibodies, and an AI Inspired New Generation of Capsids Highlight Genethon's 2024 Fall Milestones read more » |
| Dec 19 | TRYNGOLZA™ (olezarsen) approved in U.S. as first-ever treatment for adults living with familial chylomicronemia syndrome as an adjunct to diet read more » |
| Dec 23 | Sumitomo Pharma America Announces U.S. FDA Approval of GEMTESA® (vibegron) for Men with Overactive Bladder Symptoms Receiving Pharmacological Therapy for Benign Prostatic Hyperplasia read more » |
| Dec 21 | YolTech Therapeutics Announces Successful Completion of Dose Escalation Phase in Phase I Trial of YOLT-201 for ATTR read more » |
| Dec 20 | ISCT Hails Landmark US FDA Approval of RYONCIL as Major Milestone for MSC Field read more » |
| Dec 20 | FDA Approves First Medication for Obstructive Sleep Apnea read more » |
| Dec 18 | Akamis Bio Raises $60 Million for Cancer Gene Therapy, Signs Licensing Deal with Xuanzhu Biopharma read more » |
| Dec 18 | DNA-Based Vaccine Production Provides Best Shot at Profitability read more » |
| Jan 28 | MIRO2 promotes cancer invasion and metastasis via MYO9B suppression of RhoA activity read more » |
| Jan 28 | Physiological shedding and C-terminal proteolytic processing of TMEM106B read more » |
| Jan 28 | Dual-nuclease single-cell lineage tracing by Cas9 and Cas12a read more » |
| Jan 28 | Dissociation-related behaviors in mice emerge from the inhibition of retrosplenial cortex parvalbumin interneurons read more » |
| Jan 28 | Causal contributions of cell-type-specific circuits in the posterior dorsal striatum to auditory decision-making read more » |
| Dec 24 | AAV-RNAi constructs promote DRG toxicity read more » |
| Dec 24 | Cutting through the stones: Unlocking therapeutic potential with gene editing tools for primary hyperoxaluria type 1 read more » |
| Dec 23 | Current and Emerging Issues in Adeno-Associated Virus Vector-Mediated Liver-Directed Gene Therapy read more » |
| Dec 20 | Choosing the right double-barreled gun: ARI0003 takes aim at lymphoma by targeting both CD19 and BCMA read more » |
| Dec 13 | Monitoring in vivo transcription with synthetic serum markers read more » |
| Dec 04 | From promise to practice: CAR T and Treg cell therapies in autoimmunity and other immune-mediated diseases read more » |
PackGene’s Newsletter
Receive the latest news and insights to your inbox.
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
GEMMABio Pioneers Affordable Gene Therapies with $34M Seed Funding
Gene therapy startup GEMMABio, led by industry trailblazer Jim Wilson, has secured $34 million in seed funding to transform treatment options for rare diseases. Wilson, formerly of the University of Pennsylvania, founded GEMMABio and Franklin Biolabs earlier this...
Genethon Highlights Key Developments in Gene Therapy Research
December 19, 2024 – Paris, France – Genethon, a pioneering non-profit gene therapy research and development organization founded by the French Muscular Dystrophy Association (AFM-Telethon), has unveiled significant progress in its clinical and scientific endeavors as...
Sumitomo Pharma America Announces U.S. FDA Approval of GEMTESA® (vibegron) for Men with Overactive Bladder Symptoms Receiving Pharmacological Therapy for Benign Prostatic Hyperplasia
– GEMTESA® is the first and only beta-3 agonist approved for the treatment of men with OAB symptoms who are receiving pharmacological therapy for BPH – MARLBOROUGH, Mass., Dec. 23, 2024 /PRNewswire/ -- Sumitomo Pharma America, Inc. (SMPA) announced today that the U.S....
YolTech Therapeutics Announces Successful Completion of Dose Escalation Phase in Phase I Trial of YOLT-201 for ATTR
SHANGHAI, Dec. 21, 2024 /PRNewswire/ -- YolTech Therapeutics today announced updated data from its ongoing Phase I/IIa clinical trial of YOLT-201, a first-in-class CRISPR/Cas9-based in vivo gene-editing therapy for ATTR amyloidosis. The trial has completed dosing in...
Related Services
AAV Packaging Services
READ MORE
Off-the-Shelf AAV Products
READ MORE
